Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 27,698 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 27,698 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $0.46, for a total transaction of $12,741.08. Following the completion of the transaction, the director owned 655,135 shares in the company, valued at $301,362.10. This represents a 4.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $14,650.20.
• On Wednesday, May 27th, Luke Evnin sold 80,852 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.48, for a total transaction of $38,808.96.
• On Tuesday, May 26th, Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.47, for a total transaction of $31,936.50.
• On Friday, May 22nd, Luke Evnin sold 87,425 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $39,341.25.
• On Thursday, May 21st, Luke Evnin sold 36,387 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.42, for a total transaction of $15,282.54.
• On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.43, for a total transaction of $36,934.85.
• On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $28,336.50.
• On Monday, May 18th, Luke Evnin sold 22,184 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.50, for a total transaction of $11,092.00.
• On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $43,446.40.
• On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total transaction of $22,745.16.

Werewolf Therapeutics Price Performance

Shares of NASDAQ HOWL traded down $0.01 during midday trading on Friday, reaching $0.45. 278,763 shares of the stock were exchanged, compared to its average volume of 463,613. The business has a 50-day simple moving average of $0.75 and a two-hundred day simple moving average of $0.75. The company has a market capitalization of $21.87 million, a price-to-earnings ratio of -0.36 and a beta of 0.41. Werewolf Therapeutics, Inc. has a 12 month low of $0.40 and a 12 month high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. Equities research analysts expect that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Qube Research & Technologies Ltd acquired a new stake in Werewolf Therapeutics in the 2nd quarter valued at $48,000. Regal Investment Advisors LLC increased its stake in Werewolf Therapeutics by 93.3% in the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after buying an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. increased its stake in Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after buying an additional 24,003 shares during the last quarter. AQR Capital Management LLC acquired a new stake in Werewolf Therapeutics in the 1st quarter valued at $79,000. Finally, Susquehanna International Group LLP increased its stake in Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after buying an additional 13,439 shares during the last quarter. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HOWL has been the topic of a number of recent analyst reports. Wall Street Zen cut shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.